Journal profile · ONCOLOGY
Oncogenesis
ISSN 2157-9024 · Springer Nature · UNITED STATES · Founded 2012
Oncogenesis: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 6.01; fully open access; APC about USD 4,390; median 174 days to acceptance (98 articles, last 24 months); 51 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Oncogenesis is published by Springer Nature and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer, Hypoxia, and Metabolism, Epigenetics and DNA Methylation and RNA modifications and cancer, together about 23.7% of its articles. Its main subfields are Molecular Biology and Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Oncogenesis is a peer-reviewed open access online journal that publishes articles exploring mechanistic insight and molecular basis of cancer and related phenomena. It seeks to promote diverse and integrated areas of molecular biology, cell biology, oncology, and genetics. Oncogenesis seeks to encompass the breadth of the molecular biology of malignant change, and topics of particular interest include: Apoptosis Cancer metabolism Cell cycle and growth regulation Cellular oncogenes Cellular transformation and immortalization DNA damage and repair Mode of action of cancer therapeutics Molecular oncology Novel targeted therapies Senescence Tumour suppression Virus-induced oncogenesis
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology8.2%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology7.9%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology7.5%
- Ubiquitin and proteasome pathwaysBiochemistry, Genetics and Molecular Biology6.8%
- Cancer Cells and MetastasisMedicine6.7%
- Cancer-related Molecular PathwaysMedicine6.6%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5.7%
- Cancer-related gene regulationBiochemistry, Genetics and Molecular Biology5.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCPublisher website
Other: Google Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.01LetPub ·
- Impact factor (publisher) 2025
- 6Publisher website ·
- 5-year impact factor (publisher) 2025
- 6.3Publisher website ·
- CiteScore 2026-06
- 11LetPub ·
- SJR 2026-06
- 2.08LetPub ·
- SNIP 2026-06
- 1.16LetPub ·
- h-index
- 31LetPub ·
- h-index
- 94OpenAlex ·
- i10-index
- 805OpenAlex ·
- 2-year mean citedness
- 4.31OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 99.26%LetPub ·
Volume
- Articles per year
- 50LetPub ·
- Downloads per year (publisher) 2025
- 1,444,865Publisher website ·
Articles by year OpenAlex count · 1,023 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 63 | 63 | 44 |
| 2025 | 51 | 51 | 188 |
| 2024 | 42 | 42 | 440 |
| 2023 | 57 | 57 | 1,044 |
| 2022 | 69 | 69 | 2,114 |
| 2021 | 85 | 85 | 3,058 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
174 daysMedian, submission to acceptance · P25–P75 127 days – 222 days
- Acceptance to online
- median 16 days (98 articles)
- Submission to online
- median 197 days
- Sample
- 98 articles with submission and acceptance dates (119 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 26 weeksLetPub ·
- Submission to publication (journal-reported)
- about 26 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 3,590 / USD 4,390 / GBP 3,090 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 4,290 / EUR 3,490 / GBP 2,990 | — | — | |
| LetPub | GBP 2,790 / USD 3,990 / EUR 3,290 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- UNITED STATES
- Language
- English
- Founded
- 2012
- ISSN
- 2157-9024
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Oncogenesis
What CAS zone is Oncogenesis in?
In the 2025 upgraded edition of the CAS Journal Ranking, Oncogenesis is in Zone 2 of Medicine, and in Zone 2 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Oncogenesis?
The latest impact factor listed by LetPub is 6.01; CiteScore 11, h-index 94.
How long does peer review take at Oncogenesis?
Based on the dates recorded on 98 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 174 days (interquartile range 127–222 days); authors report an average review time of about 26 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Oncogenesis?
According to LetPub and DOAJ records, Oncogenesis is indexed in SCIE, Scopus and DOAJ. The journal's website also lists PMC; that list has not been checked against each database.
Is Oncogenesis open access, and what is the APC?
Oncogenesis is a fully open-access journal. APC about USD 4,390.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .